Author ORCID Identifier
Year of Publication
Doctor of Philosophy (PhD)
Dr. Greg A. Gerhardt
Dr. Craig G. van Horne
Parkinson’s disease (PD) is the second most common neurodegenerative disorder and the motor symptoms are caused by progressive loss of midbrain dopamine neurons. There is no current treatment that can slow or reverse PD. Our current “DBS-Plus” clinical trial (NCT02369003) features the implantation in vivo of autologous Schwann cells (SCs) derived from a patient’s sural nerve into the substantia nigra pars compacta (SNpc) in combination with Deep Brain Stimulation (DBS) therapy for treating patients with advanced PD.
The central hypothesis of our research is that transdifferentiated SCs within conditioned nerve tissue will deliver pro-regenerative factors to enhance the survival of the degenerating dopaminergic cells in the SNpc. The main goal of our studies is to determine if implantation of peripheral nerve tissue into SNpc in combination with DBS surgeries is safe, feasible, and can possibly slow the loss of the midbrain dopamine neurons. First, RNA sequencing was used to validate the repair phenotype of human sural nerve tissue two weeks after transaction injury. The transcriptomic analysis showed that 3641 genes were differentially expressed in conjunction with the upregulation of multiple neurotrophic factors and the enhancement of axonogenesis. Secondly, to study the neurobiology of the implant, we grafted human nerve implants into the dorsal striatum of athymic nude rats (called Neuro-Avatars). Immunostaining studies showed a remarkable survival of the implanted human SCs up to 6 months post-implantation in Neuro-Avatar animals. In addition, there were significant increases in the numbers of surviving human-derived cells in the Neuro-Avatar's using pre-degenerated human sural nerve tissue as compared to the same sural nerve tissue that was harvested in its normal state.
Finally, we studied data from 27 human subjects with PD that had received DBS plus autologous nerve-implants. The safety of the combined intervention and the progression of the motor symptoms were evaluated at baseline, 12, and 24 months using the Unified Parkinson’s Disease Rating Scale part III (UPDRS). The safety of the studies at 2 years post-implantation showed adverse events (AE’s) that were similar to those seen with standard DBS therapy. In addition, there was a significant motor improvement on the side contralateral to the tissue implantation in comparison to the ipsilateral one. Taken together, our data support that combining DBS with in vivo pre-degenerated peripheral nerve tissue containing SCs can serve as a safe and promising disease-modifying therapy to alter the progression of PD.
Digital Object Identifier (DOI)
El Seblani, Nader, "COMBINATION OF INVESTIGATIONAL CELL-BASED THERAPY AND DEEP BRAIN STIMULATION TO ALTER THE PROGRESSION OF PARKINSON’S DISEASE" (2020). Theses and Dissertations--Pharmacy. 116.
Alternative and Complementary Medicine Commons, Biotechnology Commons, Cell Biology Commons, Genomics Commons, Integrative Biology Commons, Medical Anatomy Commons, Medical Biotechnology Commons, Medical Cell Biology Commons, Medical Genetics Commons, Molecular and Cellular Neuroscience Commons, Nervous System Diseases Commons, Neurosciences Commons, Pharmacology Commons, Pharmacy and Pharmaceutical Sciences Commons